Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants.
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants.
复制标题
DOI：
10.1093/ofid/ofab268
复制
发表时间：
2021-07
影响因子：
4.2
通讯作者：
Petty LA
中科院分区：
文献类型：
--
作者：
Pogue JM;Lauring AS;Gandhi TN;Marshall VD;Eschenauer GA;Nagel JL;Baang JH;Zhou S;Valesano AL;Petty LA
靶向严重急性呼吸综合征冠状病毒2型刺突蛋白受体结合结构域（RBD）的单克隆抗体是2019年冠状病毒病的重要门诊治疗选择，可缓解疾病进展并防止住院治疗。不同RBD突变对可用单克隆抗体的疗效的影响以及将这种影响纳入治疗算法的过程尚不明确。在本文中，我们综合了关键RBD突变对美国食品药品监督管理局紧急使用授权单克隆抗体疗效影响的数据，并描述了我们在密歇根医学中心监测循环病毒突变频率的方法，并开发了一种将这些数据纳入门诊治疗途径的算法。
Monoclonal antibodies targeting the receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 spike protein are important outpatient treatment options in coronavirus disease 2019 to mitigate progression of disease and prevent hospitalization. The impact of different RBD mutations on the efficacy of the available monoclonal antibodies and processes for incorporating this impact into treatment algorithms are ill defined. Herein, we synthesize the data surrounding the impact of key RBD mutations on the efficacy of US Food and Drug Administration Emergency Use Authorized monoclonal antibodies and describe our approach at Michigan Medicine at monitoring mutation frequency in circulating virus and developing an algorithm that incorporates these data into outpatient treatment pathways.
影响因子：
64.8
作者：
Wang, Pengfei;Nair, Manoj S.;Ho, David D.
通讯作者：
Ho, David D.
影响因子：
64.5
作者：
Li, Qianqian;Wu, Jiajing;Wang, Youchun
通讯作者：
Wang, Youchun